Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
- PMID: 16163629
- DOI: 10.1086/444458
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
Abstract
Background: Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome.
Methods: The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 microg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies.
Results: The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (+/- standard error of the mean) for all 27 antigens was 3.67 +/- 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes.
Conclusions: On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.
Comment in
-
Immunity to group a streptococcal M proteins: forging a single-edged sword.Clin Infect Dis. 2005 Oct 15;41(8):1123-4. doi: 10.1086/444465. Epub 2005 Sep 12. Clin Infect Dis. 2005. PMID: 16163630 No abstract available.
Similar articles
-
Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.Vaccine. 2020 Feb 5;38(6):1384-1392. doi: 10.1016/j.vaccine.2019.12.005. Epub 2019 Dec 13. Vaccine. 2020. PMID: 31843270 Clinical Trial.
-
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.JAMA. 2004 Aug 11;292(6):709-15. doi: 10.1001/jama.292.6.709. JAMA. 2004. PMID: 15304468 Clinical Trial.
-
Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.J Infect Dis. 2006 Aug 1;194(3):316-24. doi: 10.1086/505580. Epub 2006 Jun 30. J Infect Dis. 2006. PMID: 16826479
-
Prospects for a group A streptococcal vaccine.Curr Opin Mol Ther. 2005 Feb;7(1):11-6. Curr Opin Mol Ther. 2005. PMID: 15732524 Review.
-
Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?Expert Rev Vaccines. 2009 Dec;8(12):1705-20. doi: 10.1586/erv.09.133. Expert Rev Vaccines. 2009. PMID: 19905872 Review.
Cited by
-
Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes.mSphere. 2018 Dec 19;3(6):e00617-18. doi: 10.1128/mSphere.00617-18. mSphere. 2018. PMID: 30567901 Free PMC article.
-
Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study.BMC Infect Dis. 2010 Nov 11;10:327. doi: 10.1186/1471-2334-10-327. BMC Infect Dis. 2010. PMID: 21070669 Free PMC article.
-
Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Clin Microbiol Rev. 2014 Apr;27(2):264-301. doi: 10.1128/CMR.00101-13. Clin Microbiol Rev. 2014. PMID: 24696436 Free PMC article. Review.
-
Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.PLoS One. 2017 Mar 29;12(3):e0174464. doi: 10.1371/journal.pone.0174464. eCollection 2017. PLoS One. 2017. PMID: 28355251 Free PMC article.
-
The prospect of vaccination against group A beta-hemolytic streptococci.Curr Infect Dis Rep. 2008 May;10(3):192-9. doi: 10.1007/s11908-008-0032-9. Curr Infect Dis Rep. 2008. PMID: 18510880
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical